Adicet Bio, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 3.42 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 36.81M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company’s lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
Details
| Name | Adicet Bio, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 102 |
| Founded | 1947 |
| Ceo | Chen Schor |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US0070022076 |
| Cusip | 007002207 |
| Cik | 0001720580 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Chen Schor BA, CPA, M.B.A. | Chief Executive Officer, President and Director |
| Dr. Blake Aftab Ph.D. | Senior Vice President and Chief Scientific Officer |
| Dr. Lloyd Klickstein M.D., Ph.D. | Interim Chief Medical Officer and Director |
| Brian Nicholas Harvey M.B.A. | Chief Financial Officer |
| Dr. Donald Healey Ph.D. | Chief Technology Officer |
| Amy Locke | Chief Human Resource Officer |
Contact
| Address | 131 Dartmouth Street, 3rd Floor, Boston, Massachusetts 02116, United States |
| Phone | 650 503 9095 |
| Website | https://www.adicetbio.com |